12:09 PM EST - Entheon Biomedical Corp. : Announced it has entered into a drug-supply agreement with Psygen Labs Inc. Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances ("DMT") for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency (EMA) regulatory framework. Entheon Biomedical Corp.
shares C.ENBI are trading up 1.22 percent at $0.83.
